Astec Lifesciences: CMO Business To Mitigate Risk
Moneylife Digital Team 23 May 2023
The reopening of China has dealt a heavy blow to Astec Lifesciences’(Astec’s) performance in the past two quarters. In Q4FY22-23, sales dropped by 53% y-o-y (year-on-year) to Rs127 crore. This...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Get access to complete archives
Rs 5000 + GST
 
 
Already a subscriber ? Log in
ArrayArray
Free Helpline
Legal Credit
Feedback